Gain Therapeutics Inc banner

Gain Therapeutics Inc
NASDAQ:GANX

Watchlist Manager
Gain Therapeutics Inc Logo
Gain Therapeutics Inc
NASDAQ:GANX
Watchlist
Price: 1.94 USD 7.78%
Market Cap: $74.6m

Multiples-Based Value

The Multiples-Based Value for Gain Therapeutics Inc (GANX) under the Base Case is hidden USD. Compared with the current market price of 1.94 USD, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GANX Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

GANX Competitors Multiples
Gain Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Gain Therapeutics Inc
NASDAQ:GANX
69.8m USD 0 -4 -3.6 -3.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
384.5B USD 6.2 90.5 15 20.8
US
Exact Sciences Corp
NASDAQ:EXAS
362.4B USD 111.6 -1 741.9 16 180.3 -1 827
US
Amgen Inc
NASDAQ:AMGN
189.6B USD 5.2 24.7 14.3 14.3
US
Gilead Sciences Inc
NASDAQ:GILD
173B USD 5.9 20.5 12.8 15.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.4B USD 9.5 28.8 21.6 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 18.1 13.6 15.5
AU
CSL Ltd
ASX:CSL
67.9B AUD 3.1 34.5 11.4 14.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Gain Therapeutics Inc
NASDAQ:GANX
Average P/S: 3 369 313.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.2
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
111.6
12%
9.3
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Gain Therapeutics Inc
NASDAQ:GANX
Average P/E: 36.2
Negative Multiple: -4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
90.5
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 741.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.7
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.5
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.8
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
13%
1.4
AU
CSL Ltd
ASX:CSL
34.5
10%
3.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Gain Therapeutics Inc
NASDAQ:GANX
Average EV/EBITDA: 2 324.1
Negative Multiple: -3.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
12%
1.2
US
Exact Sciences Corp
NASDAQ:EXAS
16 180.3
261%
62
US
Amgen Inc
NASDAQ:AMGN
14.3
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
18%
0.8
AU
CSL Ltd
ASX:CSL
11.4
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Gain Therapeutics Inc
NASDAQ:GANX
Average EV/EBIT: 17.2
Negative Multiple: -3.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.8
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 827 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.3
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
15.8
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
23%
0.7
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett